Ratings Gentian Diagnostics

Equities

GENT

NO0010748866

Real-time Oslo Bors Other stock markets 10:45:00 2024-04-24 am EDT			5-day change	1st Jan Change
37.6 ^NOK	0.00%		+4.44%	-9.40%

Mar. 21	Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024	CI
Mar. 21	Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company is in a robust financial situation considering its net cash and margin position.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's enterprise value to sales, at 3.2 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GENTIAN DIAGNOSTICS	-9.40%	52.72M		-
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-11.57%	7.5B		B-
DIASORIN S.P.A.	+1.76%	5.48B		B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.98%	4.61B		C
LANTHEUS HOLDINGS, INC.	+5.18%	4.47B		C
10X GENOMICS, INC.	-50.82%	3.28B		D+
ANDON HEALTH CO., LTD.	+11.23%	2.71B	-	-
VITROLIFE AB	-15.25%	2.02B		B-
MYRIAD GENETICS, INC.	-2.66%	1.69B		C
GUANGZHOU WONDFO BIOTECH CO.,LTD	-10.84%	1.74B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes